Reconsidering duration of anticoagulant therapy in VTE cases

Reconsidering duration of anticoagulant therapy in VTE cases

Researchers from the RIETE group question the usual guidelines, due to the risk of bleeding   Knowing until when we should keep anticoagulant therapy in patients who have had a thrombosis is not always easy. That’s what a study done by doctors of the RIETE group...
Reconsidering duration of anticoagulant therapy in VTE cases

Pulmonary embolism, more deadly than infarction or stroke

This treatment causes severe bleeding in 4% of patients every year, and up to 1.5% end up dying from bleeding   Pulmonary embolism (PE) is the third most common cause of vascular death after myocardial infarction and stroke. In Spain, this pathology is three...
10th VTE Multidisciplinary Forum

10th VTE Multidisciplinary Forum

A study by the RIETE Group analyses how these drugs work in pregnant women and in people with cancer or cirrhosis, among others. More than 400 experts met on April 3rd and 4th at the Palacio de Congresos of Córdoba for the 10th Venous Thromboembolism Multidisciplinary...
Estimate predicts the risk of complications in patients with PE

Estimate predicts the risk of complications in patients with PE

A decision-making tool for doctors   eStiMaTe was developed “to predict the risk of complications in patients with normal blood pressure and PE,” says David Jiménez, pneumonologist at the Hospital Universitario Ramón y Cajal of Madrid, and author of...